European Biotech Acquisition Corp.
EBACW
NASDAQ Capital Market0.52
USD
-0.01
- -
CIK
0001841258
CUSIP
G3167F128
Return %
Stock
S&P500
1Y
157.50
18.21
3Y
-31.33
63.29
5Y
-31.33
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Eduardo Bravo Fernandez de Araoz
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Johannes Vermeerplein 9 Amsterdam Netherlands
- IPO Date
- May 11, 2021
- CIK
- 0001841258
- Similar Companies
- Business
- European Biotech Acquisition Corp is a special purpose acquisition company (SPAC) primarily focused on identifying and merging with businesses in the European life sciences industry. Incorporated in 2021 and headquartered in Amsterdam, the Netherlands, the company initially raised USD 120 million through its IPO on the Nasdaq Capital Market to pursue business combinations in this sector. The company itself does not have significant operations or products but specializes in facilitating mergers, share exchanges, acquisitions, or reorganizations involving promising life sciences businesses in Europe. In March 2023, European Biotech Acquisition Corp completed a major business combination with Oculis SA, a Lausanne, Switzerland-based global biopharmaceutical company specializing in innovative ophthalmology treatments. This reverse merger transaction resulted in the formation of Oculis Holding AG, the combined company now publicly traded on the Nasdaq Global Market. Oculis develops and commercializes a pipeline of product candidates focused on topical retinal treatments, topical biologics, and disease-modifying therapies aimed at unmet medical needs such as diabetic macular edema, dry eye disease, and neuro-retina conditions including glaucoma. The core products and services following this merger center on Oculis's biopharmaceutical portfolio. These include clinical-stage candidates such as OCS-01, a topical eye drop for retinal disease; OCS-02, a topical anti-TNF therapy for dry eye disease and uveitis; and OCS-05, a neuroprotective agent targeting acute optic neuritis. The company intends to advance these therapies through late-stage clinical development, leveraging its innovative pipeline to address significant ophthalmic and retinal medical conditions in global markets. European Biotech Acquisition Corp’s latest major change was the strategic reverse merger with Oculis SA in early 2023, which transitioned the SPAC into an operating biopharmaceutical entity. This deal provided Oculis with over $109 million in gross proceeds from the trust cash and private investment in public equity (PIPE) financing, enabling accelerated clinical development and commercialization strategies. The merger reflects a significant strategic shift from a blank-check acquisition vehicle into an active biotech company with a diversified ophthalmology pipeline and global operations. The company targets markets within the ophthalmology and broader biopharmaceutical sectors, focusing on developing treatments for eye diseases with high unmet medical needs. Operating primarily in Europe and expanding globally, European Biotech Acquisition Corp leverages its association with European investment management firms experienced in healthcare to identify and support growth-stage biotech innovations. Post-merger, the company’s operations and product development are aligned under the Oculis Holding AG entity headquartered in Switzerland.